Enhancing the protective immune response against botulism

Infection and Immunity

Volumn 81, Issue 7, 2013, Pages 2638-2644

  Przedpelski, Amanda ^a   Tepp, William H ^b   Kroken, Abby R ^a   Fu, Zhuji ^a   Kim, Jung Ja P ^a   Johnson, Eric A ^b   Barbieri, Joseph T ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN A VACCINE; IMMUNOGLOBULIN G ANTIBODY; SUBUNIT VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; BOTULISM; CONTROLLED STUDY; CORRELATION ANALYSIS; CRYSTAL STRUCTURE; CRYSTALLIZATION; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; RECEPTOR BINDING; VACCINATION;

ANIMALS; BACTERIAL VACCINES; BINDING SITES; BOTULINUM TOXINS, TYPE A; BOTULISM; CELLS, CULTURED; CLOSTRIDIUM BOTULINUM; ESCHERICHIA COLI; GANGLIOSIDES; GENETIC VECTORS; IMMUNOGLOBULIN G; MICE; MODELS, ANIMAL; NEURONS; NEUTRALIZATION TESTS; POINT MUTATION; PROTEIN BINDING; RATS; SURVIVAL ANALYSIS; VACCINATION; VACCINES, SUBUNIT;

EID: 84879446130     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00382-13     Document Type: Article

References (60)

1. Gill DM. 1982. Bacterial toxins: a table of lethal amounts. Microbiol. Rev. 46:86 -94.
2. Torda C, Wolff HG. 1947. On the mechanism of paralysis resulting from toxin of Clostridium botulinum; the action of the toxin on acetylcholine synthesis and on striated muscle. J. Pharmacol. Exp. Ther. 89:320 -324.
3. Davletov B, Bajohrs M, Binz T. 2005. Beyond BOTOX: advantages and limitations of individual botulinum neurotoxins. Trends Neurosci. 28: 446-452.
4. Johnson EA. 1999. Clostridial toxins as therapeutic agents: benefits of nature's most toxic proteins. Annu. Rev. Microbiol. 53:551-575.
5. Evidente VG, Adler CH. 2010. An update on the neurologic applications of botulinum toxins. Curr. Neurol. Neurosci. Rep. 10:338 -344.
6. Kaji R. 2011. New and emerging indications of botulinum toxin therapy. Parkinsonism Relat. Disord. 17:S25-S27.
7. Lacy DB, Stevens RC. 1999. Sequence homology and structural analysis of the clostridial neurotoxins. J. Mol. Biol. 291:1091-1104.
8. Montecucco C, Schiavo G. 1995. Structure and function of tetanus and botulinum neurotoxins. Q. Rev. Biophys. 28:423- 472.
9. Lacy DB, Tepp W, Cohen AC, DasGupta BR, Stevens RC. 1998. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. 5:898 -902.
10. Takamizawa K, Iwamori M, Kozaki S, Sakaguchi G, Tanaka R, Takayama H, Nagai Y. 1986. TLC immunostaining characterization of Clostridium botulinum type A neurotoxin binding to gangliosides and free fatty acids. FEBS Lett. 201:229 -232.
11. Marxen P, Fuhrmann U, Bigalke H. 1989. Gangliosides mediate inhibitory effects of tetanus and botulinum A neurotoxins on exocytosis in chromaffin cells. Toxicon 27:849-859.
12. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, Chapman ER. 2006. SV2 is the protein receptor for botulinum neurotoxin A. Science 312:592-596.
13. Hoch DH, Romero-Mira M, Ehrlich BE, Finkelstein A, DasGupta BR, Simpson LL. 1985. Channels formed by botulinum, tetanus, and diphtheria toxins in planar lipid bilayers: relevance to translocation of proteins across membranes. Proc. Natl. Acad. Sci. U. S. A. 82:1692-1696.
14. Koriazova LK, Montal M. 2003. Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat. Struct. Biol. 10:13-18.
15. Schiavo G, Santucci A, Dasgupta BR, Mehta PP, Jontes J, Benfenati F, Wilson MC, Montecucco C. 1993. Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds. FEBS Lett. 335:99 -103.
16. Simpson LL. 2004. Identification of the major steps in botulinum toxin action. Annu. Rev. Pharmacol. Toxicol. 44:167-193.
17. Stenmark P, Dupuy J, Imamura A, Kiso M, Stevens RC. 2008. Crystal structure of botulinum neurotoxin type A in complex with the cell surface co-receptor GT1b: insight into the toxin-neuron interaction. PLoS Pathog. 4:e1000129. doi:10.1371/journal.ppat.1000129.
18. Rummel A, Mahrhold S, Bigalke H, Binz T. 2004. The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction. Mol. Microbiol. 51:631- 643.
19. Rummel A, Bade S, Alves J, Bigalke H, Binz T. 2003. Two carbohydrate binding sites in the H(CC)-domain of tetanus neurotoxin are required for toxicity. J. Mol. Biol. 326:835- 847.
20. Chen C, Fu Z, Kim JJ, Barbieri JT, Baldwin MR. 2009. Gangliosides as high affinity receptors for tetanus neurotoxin. J. Biol. Chem. 284:26569- 26577.
21. Byrne MP, Smith LA. 2000. Development of vaccines for prevention of botulism. Biochimie 82:955-966.
22. Velikanov I. 1934. Experimental immunization of man against botulism. Klin. Med. 12:1802-1806.
23. Smith LA, Rusnak JM. 2007. Botulinum neurotoxin vaccines: past, present, and future. Crit. Rev. Immunol. 27:303-318.
24. CDC. 2011 Notice of CDC's discontinuation of investigational pentavalent (ABCDE) botulinum toxoid vaccine for workers at risk for occupational exposure to botulinum toxins. MMWR Morb. Mortal. Wkly. Rep. 60:1454 -1455.
25. Torii Y, Tokumaru Y, Kawaguchi S, Izumi N, Maruyama S, Mukamoto M, Kozaki S, Takahashi M. 2002. Production and immunogenic efficacy of botulinum tetravalent (A, B, E, F) toxoid. Vaccine 20:2556 -2561.
26. Smith LA. 2009. Botulism and vaccines for its prevention. Vaccine 27(Suppl 4):D33-D39.
27. Park JB, Simpson LL, Anderson TD, Sataloff R. 2003. Immunologic characterization of spasmodic dysphonia patients who develop resistance to botulinum toxin. J. Voice 17:255-264.
28. Dertzbaugh MT, West MW. 1996. Mapping of protective and crossreactive domains of the type A neurotoxin of Clostridium botulinum. Vaccine 14:1538 -1544.
29. Clayton MA, Clayton JM, Brown DR, Middlebrook JL. 1995. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli. Infect. Immun. 63:2738 -2742.
30. Dolimbek BZ, Aoki KR, Steward LE, Jankovic J, Atassi MZ. 2007. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol. Immunol. 44:1029 -1041.
31. Shearer JD, Manetz TS, House RV. 2012. Preclinical safety assessment of recombinant botulinum vaccine A/B (rBV A/B). Vaccine 30:1917-1926.
32. Shearer JD, Vassar ML, Swiderski W, Metcalfe K, Niemuth N, Henderson I. 2010. Botulinum neurotoxin neutralizing activity of immune globulin (IG) purified from clinical volunteers vaccinated with recombinant botulinum vaccine (rBV A/B). Vaccine 28:7313-7318.
33. Baldwin MR, Tepp WH, Przedpelski A, Pier CL, Bradshaw M, Johnson EA, Barbieri JT. 2008. Subunit vaccine against the seven serotypes of botulism. Infect. Immun. 76:1314 -1318.
34. Atassi MZ, Jankovic J, Steward LE, Aoki KR, Dolimbek BZ. 2012. Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule. Immunobiology 217:17-27.
35. Qazi O, Sesardic D, Tierney R, Söderbäck Z, Crane D, Bolgiano B, Fairweather N. 2006. Reduction of the ganglioside binding activity of the tetanus toxin HC fragment destroys immunogenicity: implications for development of novel tetanus vaccines. Infect. Immun. 74:4884-4891.
36. Singh MK, Gupta G, Boopathi M, Gupta P, Chauhan V, Tomar A, Singh L, Dhaked RK. 2012. Deletion mutant comprising 198 residues of BoNT/A toxin receptor binding domain retained gt1b binding property but failed to induce protective antibody response in a mouse model. Protein Pept. Lett. 19:530 -537.
37. Elias M, Al-Saleem F, Ancharski DM, Singh A, Nasser Z, Olson RM, Simpson LL. 2011. Evidence that botulinum toxin receptors on epithelial cells and neuronal cells are not identical: implications for development of a non-neurotropic vaccine. J. Pharmacol. Exp. Ther. 336:605- 612.
38. Otwinowski Z, Minor W. 1997. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276:307-326.
39. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. 2007. Phaser crystallographic software. J. Appl. Crystallogr. 40: 658-674.
40. Fu Z, Chen C, Barbieri JT, Kim JJ, Baldwin MR. 2009. Glycosylated SV2 and gangliosides as dual receptors for botulinum neurotoxin serotype F. Biochemistry 48:5631-5641.
41. Brunger AT. 2007. Version 1.2 of the Crystallography and NMR system. Nat. Protoc. 2:2728-2733.
42. Emsley P, Cowtan K. 2004. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60:2126 -2132.
43. Blum FC, Chen C, Kroken AR, Barbieri JT. 2012. Tetanus toxin and botulinum toxin A utilize unique mechanisms to enter neurons of the central nervous system. Infect. Immun. 80:1662-1669.
44. Swaminathan S, Eswaramoorthy S. 2000. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat. Struct. Biol. 7:693- 699.
45. Kumaran D, Eswaramoorthy S, Furey W, Navaza J, Sax M, Swaminathan S. 2009. Domain organization in Clostridium botulinum neurotoxin type E is unique: its implication in faster translocation. J. Mol. Biol. 386: 233-245.
46. Benson MA, Fu Z, Kim JJ, Baldwin MR. 2011. Unique ganglioside recognition strategies for clostridial neurotoxins. J. Biol. Chem. 286: 34015-34022.
47. Binz T. 2013. Clostridial neurotoxin light chains: devices for SNARE cleavage mediated blockade of neurotransmission. Curr. Top. Microbiol. Immunol. 364:139 -157.
48. Karalewitz AP, Kroken AR, Fu Z, Baldwin MR, Kim JJ, Barbieri JT. 2010. Identification of a unique ganglioside binding loop within botulinum neurotoxins C and D-SA. Biochemistry 49:8117- 8126.
49. Kroken AR, Karalewitz AP, Fu Z, Kim JJ, Barbieri JT. 2011. Novel ganglioside-mediated entry of botulinum neurotoxin serotype D into neurons. J. Biol. Chem. 286:26828 -26837.
50. van Ginkel FW, Jackson RJ, Yoshino N, Hagiwara Y, Metzger DJ, Connell TD, Vu HL, Martin M, Fujihashi K, McGhee JR. 2005. Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract. Infect. Immun. 73:6892- 6902.
51. Ravichandran E, Al-Saleem FH, Ancharski DM, Elias MD, Singh AK, Shamim M, Gong Y, Simpson LL. 2007. Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect. Immun. 75:3043-3054.
52. Simpson LL. 2007. Balancing the benefits and risks of a botulinum toxin vaccine. Expert Rev. Vaccines 6:883- 886.
53. Ravichandran E, Gong Y, Saleem FHA, Ancharski DM, Joshi SG, Simpson LL. 2006. An initial assessment of the systemic pharmacokinetics of botulinum toxin. J. Pharmacol. Exp. Ther. 318:1343-1351.
54. Adekar SP, Takahashi T, Jones RM, Al-Saleem FH, Ancharski DM, Root MJ, Kapadnis BP, Simpson LL, Dessain SK. 2008. Neutralization of botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain. PLoS One 3:e3023. doi:10.1371/journal.pone.0003023.
55. Xie L, Mark Jones R, Glass TR, Navoa R, Wang Y, Grace MJ. 2005. Measurement of the functional affinity constant of a monoclonal antibody for cell surface receptors using kinetic exclusion fluorescence immunoassay. J. Immunol. Methods 304:1-14.
56. Takahashi T, Joshi SG, Al-Saleem F, Ancharski D, Singh A, Nasser Z, Simpson LL. 2009. Localization of the sites and characterization of the mechanisms by which anti-light chain antibodies neutralize the actions of the botulinum holotoxin. Vaccine 27:2616 -2624.
57. Corbett CR, Ballegeer E, Weedmark KA, Elias MD, Al-Saleem FH, Ancharski DM, Simpson LL, Berry JD. 2011. Epitope characterization of sero-specific monoclonal antibody to Clostridium botulinum neurotoxin type A. Hybridoma 30:503-510.
58. Atassi MZ, Dolimbek BZ, Hayakari M, Middlebrook JL, Whitney B, Oshima M. 1996. Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855-1296 with antitoxin antibodies from three host species. J. Protein Chem. 15:691-700.
59. Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, Montgomery VA, Sheridan R, Blake R, Smith LA, Marks JD. 2002. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc. Natl. Acad. Sci. U. S. A. 99:11346 -11350.
60. Pirazzini M, Rossetto O, Bertasio C, Bordin F, Shone CC, Binz T, Montecucco C. 2013. Time course and temperature dependence of the membrane translocation of tetanus and botulinum neurotoxins C and D in neurons. Biochem. Biophys. Res. Commun. 430:38-42.